RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors
Open Access
- 15 October 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (20), 9347-9354
- https://doi.org/10.1158/0008-5472.can-05-1647
Abstract
RUNX3 is inactivated at high frequency in many tumors. However, in most cases, inactivation is caused by silencing of the gene due to promoter hypermethylation. Because epigenetic silencing is known to affect many major tumor suppressor genes in cancer cells, it is not clear whether RUNX3 is primarily responsible for the induction of carcinogenesis in these cases, except for the gastric cancer cases that we reported previously. We investigated genetic and epigenetic alterations of RUNX3 in 124 bladder tumor cases and seven bladder tumor–derived cell lines. Here we show that RUNX3 is inactivated by aberrant DNA methylation in 73% (90 of 124) of primary bladder tumor specimens and 86% (six of seven) of bladder tumor cell lines. In contrast, the promoter regions of 20 normal bladder mucosae were unmethylated. Importantly, one patient bore missense mutations, each of which resulted in amino acid substitutions in the highly conserved Runt domain. The mutations abolished the DNA-binding ability of RUNX3. A second patient had a single nucleotide deletion within the Runt domain coding region that resulted in truncation of the protein. RUNX3 methylation was a significant risk factor for bladder tumor development, superficial bladder tumor recurrence, and subsequent tumor progression. These results strongly suggest that inactivation of RUNX3 may contribute to bladder tumor development and that promoter methylation and silencing of RUNX3 could be useful prognostic markers for both bladder tumor recurrence and progression.This publication has 41 references indexed in Scilit:
- The runx genes: gain or loss of function in cancerNature Reviews Cancer, 2005
- Epigenetic inactivation ofRUNX3 in microsatellite unstable sporadic colon cancersInternational Journal of Cancer, 2004
- Tumor suppressor activity of RUNX3Oncogene, 2004
- Hypermethylation of the RUNX3 Gene Promoter in Testicular Yolk Sac Tumor of InfantsThe American Journal of Pathology, 2003
- Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patientsInternational Journal of Cancer, 2003
- DNA methylation, methyltransferases, and cancerOncogene, 2001
- Deletions of the INK4A Gene in Superficial Bladder Tumors: Association with RecurrenceThe American Journal of Pathology, 1999
- Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasiaNature Genetics, 1997
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Clinical Implications of the p53 Tumor-Suppressor GeneThe New England Journal of Medicine, 1993